Multicomponent antibiotic substances produced by fermentation: Implications for regulatory authorities, critically ill patients and generics

International Journal of Antimicrobial Agents

Volumn 43, Issue 1, 2014, Pages 1-6

  Brink, Adrian J ^a   Richards, Guy A ^b   Colombo, Gaia ^c   Bortolotti, Fabrizio ^c   Colombo, Paolo ^d   Jehl, François ^e  

^a MILPARK HOSPITAL   (South Africa)

^b UNIVERSITY OF THE WITWATERSRAND   (South Africa)

^c UNIVERSITY OF FERRARA   (Italy)

^d UNIVERSITY OF PARMA   (Italy)

^e UNIVERSITY HOSPITAL OF STRASBOURG   (France)

Author keywords

Colistin; Generic; ICU; Pharmacokinetics; Subcomponent

Indexed keywords

COLISTIMETHATE; COLISTIN; COLISTIN A; GENERIC DRUG; POLYMYXIN E2; TEICOPLANIN; TEICOPLANIN A2-1; TEICOPLANIN A2-2; TEICOPLANIN A2-3; TEICOPLANIN A2-4; TEICOPLANIN A2-5; UNCLASSIFIED DRUG; VANCOMYCIN;

AMINO ACID COMPOSITION; ANTIMICROBIAL ACTIVITY; CRITICALLY ILL PATIENT; DRUG CONTROL; DRUG DISTRIBUTION; DRUG HALF LIFE; FERMENTATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; LIPID COMPOSITION; LIPOPHILICITY; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PAENIBACILLUS POLYMYXA; PRINCIPAL COMPONENT ANALYSIS; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW;

COLISTIN; GENERIC; ICU; PHARMACOKINETICS; POLYMYXIN E(1-2); SUBCOMPONENT; TEICOPLANIN A(2-1)-A(2-5);

AMINO ACIDS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; COLISTIN; COMPLEX MIXTURES; CRITICAL ILLNESS; DRUG APPROVAL; FATTY ACIDS; FERMENTATION; HUMANS; PROTEIN BINDING; SOLUBILITY; TEICOPLANIN; TREATMENT OUTCOME;

EID: 84890792786     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2013.06.013     Document Type: Note

References (34)

1. C. Taurino, L. Frattini, G.L. Marcone, and F. Marinelli Actinoplanes teichomyceticus ATCC 31121 as a cell factory for producing teicoplanin Microbiol Cell Fact 10 2011 82 95
2. A. Borghi, E. Duncan, L.F. Zerilli, and G.C. Lancini Factors affecting the normal and branched-chain acyl moieties of teicoplanin components produced by Actinoplanes teichomyceticus J Gen Microbiol 137 1991 587 592
3. A. Rossi, F. Buttini, P. Colombo, M. Mor, D. Pala, and F. Bortolotti Complex product composition generates risks for generic substitution also with dosage forms for intravenous administration Int J Pharm 451 2013 50 56
4. I. Harding, and F. Sorgel Comparative pharmacokinetics of teicoplanin and vancomycin J Chemother 12 2000 15 20
5. K. Hanada, A. Kobayashi, Y. Okamori, T. Kimura, and H. Ogata Improved quantitative determination of total and unbound concentrations of six teicoplanin components in human plasma by high performance liquid chromatography Biol Pharm Bull 28 2005 2023 2025
6. A. Bernaregi, A. Danese, A. Cometti, G. Buniva, and M. Rowland Pharmacokinetics of individual components of teicoplanin in man J Pharmacokinet Biopharm 18 1990 525 543
7. K. Hanada, S. Ikari, Y. Koukaki, A. Utena, T. Kimura, and K. Hamano Comparison of pharmacokinetics of individual teicoplanin components in patients Biol Pharm Bull 30 2007 952 954
8. H. van der Waterbeemt, D.A. Smith, and B.C. Jones Lipophilicity in PK design: methyl, ethyl, futile J Comput Aided Mol Des 15 2001 273 286
9. J. Roberts, M. Bassetti, J. Dewaele, G. Dimopoulos, D. Koulenti, and C. Martin Variability of protein binding of teicoplanin and achievement of TDM targets: lessons from the DALI study 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 27-30 April 2013; Berlin, Germany. ESCMID 2013 Abstract P926
10. M. Ulldemolins, J.A. Roberts, J. Rello, D.L. Paterson, and J. Lipman The effect of hypoalbuminaemia on optimizing antibacterial dosing in critically ill patients Clin Pharmacokinet 50 2011 99 110
11. R. Yano, T. Nakamura, H. Tsukamoto, T. Igarashi, N. Goto, and Y. Wakiya Variability in teicoplanin protein binding and its prediction using serum albumin concentrations Ther Drug Monit 29 2007 399 403
12. A.J. Brink, G.A. Richards, R.R. Cummins, and J. Lambson Recommendations to achieve rapid therapeutic teicoplanin plasma concentrations in adult hospitalized patients treated for sepsis Int J Antimicrob Agents 32 2008 455 458
13. A. Borghi, C. Coronelli, L. Faniuolo, G. Allieve, R. Pallanza, and G.G. Gallo Teichomycins, new antibiotics from Actinoplanes teichomyceticus nov. sp. IV. Separation and characterization of the components of teichomycin (teicoplanin) J Antibiot (Tokyo) 6 1984 615 620
14. European Patent Specification. A teicoplanin composition with improved antibiotic activity. Bulletin 2006/52. 27 December 2006. https://data.epo.org/ publication-server/pdf-document?pn=1516626&ki=B1&cc=EP [accessed 20.03.13].
15. European Medicines Agency (EMEA), Committee for Medicinal Products for Human Use (CHMP). Annex II. Scientific conclusions and grounds for refusal: Hospira teicoplanin. 25 June 2009. http://www.ema.europa.eu/docs/en-GB/document- library/Referrals-document/Teicoplanin-Hospira-29/WC500095134.pdf [accessed 19.02.13].
16. World Health Organization. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Geneva, Switzerland: WHO; 2006. WHO Technical Report Series No. 937. http://apps.who.int/prequal/info-general/documents/TRS937/WHO-TRS-937-annex7- eng.pdf [accessed 15.03.13].
17. European Medicines Agency. Assessment report. Review under Article 5(3) of Regulation (EC) No 726/2004. Teicoplanin. Procedure no: EMEA/H/A-5(3)/1315. EMA; 21 March 2013. http://www.ema.europa.eu/docs/en-GB/document-library/Report/ 2013/04/WC500142229.pdf [accessed 24.04.13].
18. S. Biswas, J. Brunel, J. Dubus, M. Reynaud-Gaubert, and J. Rolain Colistin: an update on the antibiotic of the 21st century Expert Rev Anti Infect Ther 10 2012 917 934
19. J. Li, R.W. Milne, R.L. Nation, J.D. Turnidge, and K. Coulthard Stability of colistin and colistin methanesulfonate in aqueous media and plasma as determined by high-performance liquid chromatography Antimicrob Agents Chemother 47 2003 1364 1370
20. M.E. Falagas, and S.K. Kasiakou Colistin: the revival of polymyxins for the management of multidrug-resistant Gram-negative bacterial infections Clin Infect Dis 40 2005 1333 1341
21. J.A. Roberts, and J. Lipman Editorial commentary: closing the loop - a colistin clinical study to confirm dosing recommendations from PK/PD modeling Clin Infect Dis 54 2012 1727 1729
22. D. Decolin, P. Leroy, A. Nicolas, and P. Archimbault Hyphenated liquid chromatographic method for the determination of colistin residues in bovine tissues J Chromatogr Sci 35 1997 557 564
23. P. Gobin, F. Lemaitre, S. Marchand, W. Couet, and J-C. Oliver Assay of colistin and colistin methanesulfonate in plasma and urine by liquid chromatography-tandem mass spectrometry Antimicrob Agents Chemother 54 2010 1941 1948
24. S.M. Garonzik, J. Li, V. Thamlikitkul, D.L. Paterson, S. Shoham, and J. Jacob Population pharmacokinetics of colistin methanesulfonate and formed colistin in critically ill patients from a multicenter study provide dosing suggestions for various categories of patients Antimicrob Agents Chemother 55 2011 3284 3294
25. M. Shaheen, J. Li, A.C. Ross, J.C. Vederas, and S.E. Jensen Paenibacillus polymyxa PKB1 produces variants of polymyxin B-type antibiotics Chem Biol 18 2011 1640 1648
26. Z. Kassamali, W. Wang, R.N. Jones, J. Rotschafer, L. Danziger, and R. Prince Is what you see what you get? Product variation in clinical and reference formulations of polymyxin B 23rd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 27-30 April 2013; Berlin, Germany. ESCMID 2013 Abstract O581 (Oral)
27. J.A. Orwa, C. Govaerts, R. Busson, E. Roets, A. Van Schepdael, and J. Hoogmartens Isolation and structural characterization of colistin components J Antibiot (Tokyo) 54 2001 595 599
28. J. Li, J. Turnidge, R. Milne, R.L. Nation, and K. Coulthard In vitro pharmacodynamic properties of colistin and colistin methanesulfonate against Pseudomonas aeruginosa isolates from patients with cystic fibrosis Antimicrob Agents Chemother 45 2001 781 785
29. R. Imberti, G.A. Lotti, M. Cusato, and M. Regazzi Response to: colistin penetration in the alveolar lining fluid of critically ill patients treated with IV colistimethate sodium Chest 139 2011 233 234
30. C. Tan, J. Li, and R.L. Nation Activity of colistin against heteroresistant Acinetobacter baumannii and emergence of resistance in an in vitro pharmacokinetic/pharmacodynamic model Antimicrob Agents Chemother 51 2007 3413 3415
31. L. Bai, Z. Ma, G. Yang, J. Yang, and J. Cheng A simple HPLC method for the separation of colistimethate sodium and colistin sulphate J Chromatogr Seperat Tech 2 2011 1 4
32. Colistin sulfate (Ph. Eur. monograph 0320). In: British Pharmacopoeia 2012. Volumes I and II. Monographs: medicinal and pharmaceutical substances. http://bp2012.infostar.com.cn/Bp2012.aspx?a=query&title= %22Colistin+Sulfate%22&tab=a-z+index&l=C&xh=1 [accessed 14.04.13].
33. Committee for Medicinal Products for Human Use (CHMP). Guideline on similar biological medicinal products. EMEA; 30 October 2005. CHMP/437/04. http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/ 09/WC500003517.pdf [accessed 28.03.13].
34. French Agency for Safety of Health Products [Agence française de sécurité sanitaire des produits de santé (AFSSAPS)]. Summary of 'Information on the actions of the AFSSAPS concerning generic injectable antibiotics'. AFSSAPS; March 2013. http://ansm.sante.fr/var/ansm- site/storage/original/application/18c0540392a89453c92ffc064b5b8f30.pdf [accessed 10.04.13].